MGTA News and Press, Magenta Therapeutics Inc. From 08/16/19

Note: The following article assumes you are familiar with my introductory article on Magenta. Introduction Magenta Therapeutics ( MGTA ) first came on my radar in June of last year before it began trading on Nasdaq. I was interested by their broad, practice-changing portfolio an...

-- Initiated Phase 1 study of MGTA-145 first-line mobilization therapy, enrollment on track for data presentation before end of year -- -- Presented updated Phase 2 clinical data on MGTA-456 cell therapy in patients with inherited metabolic disorders at American Academy of Neurology a...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company is scheduled to present at the Wedbush PacGrow Healthcare Conference on August 13, ...

Reissuing release dated June 24th, 2019 to correct for searching purposes. The corrected release reads: MAGENTA THERAPEUTICS APPOINTS ANNE MCGEORGE TO BOARD OF DIRECTORS Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company is scheduled to present at the Goldman Sachs Global Healthcare Conference on June ...

Shares of Magenta Therapeutics ( MGTA ) have risen by around 25% since my August 20th article suggested this IPO should be on readers' radar. To be fair, at one point the stock lost almost two-thirds of its value before rebounding this year. While I revisited this one earlier in ROTY, it's...

The iShares Russell 2000 ETF ( IWM ) tracks a basket of small-cap stocks including companies not typically part of large-cap broad market indexes like the S&P 500. Year to date, the ETF is up 15%, but still 10% below its all-time high set in August of 2018, which is in contrast to the S&am...

CymaBay Therapeutics ( CBAY ) : The company announced first quarter financial results, with management highlighting the fact that enrollment was completed one quarter ahead of schedule in the phase 2b study of seladelpar in NASH patients (52-week, dose-ranging trial). Topline data for chang...

Magenta Therapeutics (NASDAQ: MGTA ): Q1 GAAP EPS of -$0.44 beats by $0.13 . More news on: Magenta Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

-- Dosed first subjects in Phase 1 study of MGTA-145 first-line mobilization therapy -- -- Presented updated Phase 2 clinical data on MGTA-456 cell therapy in patients with inherited metabolic disorders at American Academy of Neurology annual meeting -- -- Presented preclinical da...